Medicure to Present at Two Major Biotech Conferences

[Medicure via BizWire]

WINNIPEG, Manitoba--(BUSINESS WIRE)--April 30, 2004--Medicure Inc.
(Amex:MCU) (TSX:MPH), a cardiovascular drug discovery and development
company, is pleased to announce that it has been selected to present
at two major biotech conferences in May. On May 12, 2004, Medicure
will be making a corporate presentation at the Rodman & Renshaw
Techvest Global Healthcare Conference in London, England, and also on
May 12, the Company will present at the BioFinance 2004 Conference in
Toronto.
The London Conference, the first of two Rodman & Renshaw Techvest
Global Healthcare Conferences - the second is in New York in October
- will bring together medical and scientific experts and executives
from the European and North American biotechnology and pharmaceutical
industries, along with institutional investors, analysts and venture
capitalists following the life sciences sector. Corporate
presentations will be delivered from leading biotech companies from
around the world. Albert D. Friesen, Ph.D., Medicure's President and
CEO will deliver the Company's presentation at 9:25 a.m., London
time. His presentation will be 20 minutes in duration and will be
followed by a 30-minute breakout session and one-on-one meetings.
In the afternoon of May 12, Dawson Reimer, Medicure's
Vice-President of Operations, will make a corporate presentation at
BioFinance 2004, Canada's largest annual life sciences business
gathering. Medicure's presentation will commence at 2 p.m. Eastern
Time in the Trinity I Meeting Room of the Marriott Hotel in downtown
Toronto. BioFinance 2004 will feature presentations from more than
120 Canadian, U.S. and European public and private sector life
science companies. More than 700 delegates, including investment
bankers, institutional investors, pension fund managers, venture
capitalists, analysts and professional service firms, will attend the
conference.
"We are pleased to have the opportunity to present the Medicure
story to audiences at these two important biotech conferences," said
Dr. Friesen, Ph.D. "We have had a very exciting start to 2004 and we
look forward to our participation on the world stage at conferences
of this stature.
"Our involvement in these conferences reflects the growing
recognition of Medicure internationally and they represent
exceptional venues for reaching sophisticated groups of institutional
investors, investment bankers and financial analysts," he added.
"They also allow us to broaden Medicure's exposure and enhance our
visibility in the Canadian, U.S. and European markets."

About Medicure Inc.

Medicure Inc. is a cardiovascular drug discovery and development
Company focused on developing effective therapeutics for unmet needs
in the field of cardiovascular medicine. The Company's lead drug,
MC-1, is focused on the prevention and treatment of ischemia,
ischemic reperfusion injury, and stroke. The cardiovascular and
stroke market is the largest pharmaceutical sector with annual global
sales of over US $70 billion. Medicure recently commenced enrollment
in its Phase II/III MEND-CABG clinical trial, which will evaluate the
cardioprotective and neuroprotective effects of MC-1 in patients
undergoing high-risk Coronary Artery Bypass Graft (CABG) surgery.
The Company's second product candidate, MC-4232, is being
targeted as a treatment for hypertensive patients, particularly for
those with difficult to treat hypertension complicated by co-existing
diabetes. Approximately 73% of the more than 50 million adult
Americans who have hypertension, are not adequately treated.
The Company also has a medicinal chemistry-based Drug Discovery
Program, which is similarly focused on advancing novel therapeutics
to address unmet cardiovascular needs.

This news release contains forward-looking statements that
involve risks, which may cause actual results to differ materially
from the statements made, and accordingly may be deemed to be
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The forward-looking statements are made as of the date hereof, and
the Company disclaims any intention and has no obligation or
responsibility to update or revise any forward-looking statements,
whether as a result of new information, future events, or otherwise.
-=-=-
C O P Y R I G H T * R E M I N D E R

This article is Copyright 2004 by Business Wire.
All articles in the clari.* news hierarchy are Copyrighted and licensed
to ClariNet Communications Corp. for distribution. Except for articles
in the biz.clarinet newsgroups, only paid subscribers may access
these articles. Any unauthorized access, reproduction or transmission
is strictly prohibited.
We offer a reward to the person who first provides us with
information that helps stop those who distribute or receive our news
feeds without authorization. Please send reports to rew...@clari.net.
[Use in...@clari.net for sales or other inquiries.]

Details on the use of ClariNet material and other info can be found in
the user documentation section of <<our web page>> <http://www.clari.net>.